In vivo and in vitro pharmacological characterization of SVT‐40776, a novel M 3 muscarinic receptor antagonist, for the treatment of overactive bladder

• Published in: British journal of pharmacology Vol. 156; no. 5; pp. 807 - 817
• Main Authors: Salcedo, C, Davalillo, S, Cabellos, J, Lagunas, C, Balsa, D, Pérez‐del‐Pulgar, S, Ballarín, M, Fernández, AG
• Format: Journal Article
• Language: English
• Published: 01-03-2009
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.2008.00082.x

Background and purpose: 
Highly selective M
3
muscarinic receptor antagonists may represent a better treatment for overactive bladder syndrome, diminishing side effects. Cardiac side effects of non‐selective antimuscarinics have been associated with activity at M
2
receptors as these receptors are mainly responsible for muscarinic receptor‐dependent bradycardia. We have investigated a novel antimuscarinic, SVT‐40776, highly selective for M
3
over M
2
receptors (Ki = 0.19 nmol·L
−1
for M
3
receptor affinity). This study reports the functional activity of SVT‐40776 in the bladder, relative to its activity in atria.
Experimental approach: 
In vitro
and
ex vivo
(oral dosing) inhibition of mouse detrusor and atrial contractile responses to carbachol were used to study the functional activity of SVT‐40776. The
in vivo
efficacy of SVT‐40776 was characterized by suppression of isovolumetric spontaneous bladder contractions in anaesthetized guinea pigs after intravenous administration.
Key results: 
SVT‐40776 was the most potent in inhibiting carbachol‐induced bladder contractions of the anti‐cholinergic agents tested, without affecting atrial contractions over the same range of concentrations. SVT‐40776 exhibited the highest urinary versus cardiac selectivity (199‐fold). In the guinea pig
in vivo
model, SVT‐40776 inhibited 25% of spontaneous bladder contractions at a very low dose (6.97 µg·kg
−1
i.v), without affecting arterial blood pressure.
Conclusions and implications: 
SVT‐40776 is a potent inhibitor of M
3
receptor‐related detrusor contractile activity. The absence of effects on isolated atria preparations represents an interesting characteristic and suggests that SVT‐40776 may lack unwanted cardiac effects; a feature especially relevant in a compound intended to treat mainly elderly patients.
British Journal of Pharmacology
(2009) doi:10.1111/j.1476‐5381.2008.00082.x